Patient characteristics
| Characteristic, n (%) . | BMT . | PBSCT . | ||||
|---|---|---|---|---|---|---|
| Japanese (n = 283) . | White (n = 69) . | P . | Japanese (n = 130) . | White (n = 639) . | P . | |
| Patient age, median (range), y | 45 (18-69) | 47 (18-67) | .25 | 44 (18-67) | 55 (18-75) | <.001 |
| Sex | .10 | .77 | ||||
| Male | 170 (60) | 49 (71) | 74 (57) | 375 (59) | ||
| Female | 113 (40) | 20 (29) | 56 (43) | 264 (41) | ||
| Disease | <.001 | <.001 | ||||
| AML | 120 (42) | 32 (46) | 49 (38) | 220 (34) | ||
| MDS/MPN | 27 (10) | 10 (14) | 15 (12) | 141 (22) | ||
| ALL | 41 (14) | 14 (20) | 14 (11) | 57 (9) | ||
| CML/CLL | 3 (1) | 12 (17) | 2 (2) | 67 (10) | ||
| Malignant lymphoma | 91 (32) | 1 (1) | 50 (38) | 100 (16) | ||
| Plasma cell neoplasms | 1 (< 1) | 0 (0) | 0 (0) | 54 (8) | ||
| Disease Risk Index | .001 | .15 | ||||
| Low | 23 (8) | 14 (20) | 11 (8) | 88 (14) | ||
| Intermediate | 182 (64) | 29 (42) | 75 (58) | 318 (50) | ||
| High/very high | 78 (28) | 26 (38) | 44 (34) | 233 (36) | ||
| HCT–comorbidity index at transplantation | <.001 | <.001 | ||||
| 0-1 | 232 (82) | 19 (28) | 109 (84) | 135 (21) | ||
| ≥2 | 51 (18) | 47 (68) | 21 (16) | 463 (72) | ||
| Unknown | 0 (0) | 3 (4) | 0 (0) | 41 (6) | ||
| Donor type | 1.0 | <.001 | ||||
| Related | 20 (7) | 4 (6) | 127 (98) | 275 (43) | ||
| Unrelated | 263 (93) | 65 (94) | 3 (2) | 364 (57) | ||
| HLA matching | .01 | 1.0 | ||||
| Match | 152 (54) | 49 (71) | 109 (84) | 533 (83) | ||
| Mismatch | 131 (46) | 20 (29) | 22 (16) | 106 (17) | ||
| Donor–patient sex combination | .008 | .32 | ||||
| Female donor to male patient | 42 (15) | 20 (29) | 36 (28) | 151 (24) | ||
| Others | 241 (85) | 49 (71) | 94 (72) | 488 (76) | ||
| Conditioning intensity | <.001 | .50 | ||||
| Myeloablative | 177 (63) | 69 (100) | 71 (55) | 328 (51) | ||
| Reduced intensity | 106 (37) | 0 (0) | 59 (45) | 311 (49) | ||
| GVHD prophylaxis | .71 | <.001 | ||||
| CNI alone | 6 (2) | 0 (0) | 40 (28) | 8 (1) | ||
| CNI + MTX | 267 (94) | 67 (97) | 86 (66) | 284 (44) | ||
| CNI + MMF | 10 (4) | 2 (3) | 4 (3) | 347 (54) | ||
| Characteristic, n (%) . | BMT . | PBSCT . | ||||
|---|---|---|---|---|---|---|
| Japanese (n = 283) . | White (n = 69) . | P . | Japanese (n = 130) . | White (n = 639) . | P . | |
| Patient age, median (range), y | 45 (18-69) | 47 (18-67) | .25 | 44 (18-67) | 55 (18-75) | <.001 |
| Sex | .10 | .77 | ||||
| Male | 170 (60) | 49 (71) | 74 (57) | 375 (59) | ||
| Female | 113 (40) | 20 (29) | 56 (43) | 264 (41) | ||
| Disease | <.001 | <.001 | ||||
| AML | 120 (42) | 32 (46) | 49 (38) | 220 (34) | ||
| MDS/MPN | 27 (10) | 10 (14) | 15 (12) | 141 (22) | ||
| ALL | 41 (14) | 14 (20) | 14 (11) | 57 (9) | ||
| CML/CLL | 3 (1) | 12 (17) | 2 (2) | 67 (10) | ||
| Malignant lymphoma | 91 (32) | 1 (1) | 50 (38) | 100 (16) | ||
| Plasma cell neoplasms | 1 (< 1) | 0 (0) | 0 (0) | 54 (8) | ||
| Disease Risk Index | .001 | .15 | ||||
| Low | 23 (8) | 14 (20) | 11 (8) | 88 (14) | ||
| Intermediate | 182 (64) | 29 (42) | 75 (58) | 318 (50) | ||
| High/very high | 78 (28) | 26 (38) | 44 (34) | 233 (36) | ||
| HCT–comorbidity index at transplantation | <.001 | <.001 | ||||
| 0-1 | 232 (82) | 19 (28) | 109 (84) | 135 (21) | ||
| ≥2 | 51 (18) | 47 (68) | 21 (16) | 463 (72) | ||
| Unknown | 0 (0) | 3 (4) | 0 (0) | 41 (6) | ||
| Donor type | 1.0 | <.001 | ||||
| Related | 20 (7) | 4 (6) | 127 (98) | 275 (43) | ||
| Unrelated | 263 (93) | 65 (94) | 3 (2) | 364 (57) | ||
| HLA matching | .01 | 1.0 | ||||
| Match | 152 (54) | 49 (71) | 109 (84) | 533 (83) | ||
| Mismatch | 131 (46) | 20 (29) | 22 (16) | 106 (17) | ||
| Donor–patient sex combination | .008 | .32 | ||||
| Female donor to male patient | 42 (15) | 20 (29) | 36 (28) | 151 (24) | ||
| Others | 241 (85) | 49 (71) | 94 (72) | 488 (76) | ||
| Conditioning intensity | <.001 | .50 | ||||
| Myeloablative | 177 (63) | 69 (100) | 71 (55) | 328 (51) | ||
| Reduced intensity | 106 (37) | 0 (0) | 59 (45) | 311 (49) | ||
| GVHD prophylaxis | .71 | <.001 | ||||
| CNI alone | 6 (2) | 0 (0) | 40 (28) | 8 (1) | ||
| CNI + MTX | 267 (94) | 67 (97) | 86 (66) | 284 (44) | ||
| CNI + MMF | 10 (4) | 2 (3) | 4 (3) | 347 (54) | ||
CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CNI, calcineurin inhibitor; MMF, mycophenolate mofetil; MPN, myeloproliferative neoplasms; MTX, methotrexate.